Anne-Renee Van Der Vuurst de Vries

Anne-Renée joined Sonoma Biotherapeutics in January 2020 as Director of Product Validation, with nearly 20 years of experience in industry settings, developing small molecule, protein, and CAR-T therapeutic approaches for oncology and autoimmune diseases.

Most recently, she served as Director within the Immuno-Oncology and Cellular Therapy Therapeutic Research Center of Celgene where she was responsible for Immuno-Oncology target validation and CAR & TCR discovery. Prior to her 5-year tenure at Celgene, she had leadership positions in the Discovery Immunology Department at Novo Nordisk Research Center, where she was responsible for antibody phage display and discovery platforms, and at Addex Pharmaceuticals focused on the identification of allosteric modulators for inflammatory diseases. Early in her career, she focused on identifying novel tumor targets at both Spaltudaq and Amgen.

Anne-Renée began her career in the industry as a postdoctoral fellow at Immunex in Cancer Biology following her Ph.D. degree in Immunology at the University of Utrecht in the Netherlands.

Among her duties at Sonoma, Anne-Renée and her team are responsible for characterizing and identifying the product leads that move to the clinic.